Loading...
•
Sep 30, 2022
uniQure Q3 2022 Earnings Report
uniQure reported its Q3 2022 financial results and highlighted recent company progress.
Key Takeaways
uniQure's Q3 2022 collaboration revenue was $1.4 million, R&D expenses were $48.1 million, and SG&A expenses were $13.3 million. The company's net loss for the quarter was $47.9 million, or $1.02 per share. As of September 30, 2022, the company held $440.3 million in cash and cash equivalents.
Patient enrollment at the higher dose of AMT-130 to resume in European Phase Ib/II study following Data Safety Monitoring Board recommendation.
U.S. and European pre-approval inspections of Company’s Lexington, MA manufacturing site completed with EMA issuing Good Manufacturing Certificate.
Virtual investor event focused on next pipeline program, AMT-260 investigational gene therapy for refractory temporal lobe epilepsy, to be held on Tuesday, November 29, 2022
Company held cash and cash equivalents of $440.3 million as of September 30, 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...